

Jeffrey A. Sosman MD.: Short Biographical Profile

Dr. Jeffrey Sosman is an experienced clinical investigator whose career has been vested in the immune-based and targeted therapy of melanoma and renal cell carcinoma. He has played a significant role in the clinical development of the immune checkpoint inhibitors, both Ipilimumab (anti-CTLA-4) and Nivolumab (anti-PD-1). In addition Jeff has lead early trials demonstrating efficacy of BRAF inhibitors in patients with *BRAF*^{V600} melanoma. He has been involved in efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance. Understanding and manipulating the tumor microenvironment is a major avenue to enhance the effects of immune checkpoint inhibitors. More recently, he has also turned to focus on ICP induced toxicity (autoimmunity) and understanding their mechanisms. At the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, he is a Professor of Medicine and co-leads the Translational Research in Solid Tumors (TRIST) program in the Cancer Center. He also directs junior clinical faculty development and co-directs the expanding Cancer Immunology program within the Cancer Center. He continues to be determined to bring creative immune based trials to cancers across a number of histologies. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is his highest priority.

He is also the first Mary Hendrickson-Johnson Melanoma American Cancer Society Research Professor since 2008 for his long term achievements in melanoma clinical research.